Additionally, this would not be a mixed-phenotype acute leukemia, T/myeloid, not otherwise specifi ed, as that requires positivity for cytoplasmic CD3 or surface CD3, and that was conspicuously absent. 5 Therefore, the appropriate workup and treatment should have essentially followed the course for acute myeloid leukemia, 4 which is unclear from the present report as there is no mention of a molecular workup (eg, for FLT3 and NPM1 mutations). This would, in turn, have important treatment and prognostic implications. 6 The reason for my comments is to bring to light the importance of exact pathologic diagnosis, especially when dealing with leukemia. We currently have a host of treatment options and prognostic tools for the various types of acute myeloid leukemia, but only when a clear and precise pathologic diagnosis is given. 
